OXiGENE (OXGN) In-Licenses Rights to Promising Program for Neuroendocrine Tumors
6/22/2012 9:50:28 AM
SOUTH SAN FRANCISCO, Calif., June 21, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the establishment of an exclusive, worldwide licensing agreement with Angiogene Pharmaceuticals Ltd., a U.K.-based drug development company, for data, development plans, know-how, patents and other intellectual property rights relative to their vascular disrupting agent (VDA) program for neuroendocrine cancers, focused specifically on carcinoid syndrome. OXiGENE plans to leverage these assets for the development and potential commercialization of ZYBRESTAT to treat carcinoid syndrome associated with metastatic carcinoid and neuroendocrine tumors, which represents a large and growing market opportunity with significant unmet medical need.
comments powered by